期刊文献+

Oncological and functional results following operation for giant cell tumour of bone

Oncological and functional results following operation for giant cell tumour of bone
下载PDF
导出
摘要 Objective:Giant cell tumours(GCT) represent one of the most common benign tumours of bone. However, despite its benign nature they are aggressive lesions that have a tendency to recur. This study aims to report experience with the treatment of GCTs, and reviews the relationship between surgical management and clinical outcome. Methods:A retrospective review was performed with 70 patients (32 males and 38 females) who presented to our institution between 1991 and 2001 with GCT of bone. An evaluation of the oncological and functional results was conducted and patients were divided into three groups according to the treatment method; Group Ⅰ :(46 patients) intralesional curettage and adjuvant therapy and packing with filling materials. Group Ⅱ :(18 patients) en-bloc resection and arthrodesis or reconstruction. Group Ⅲ :(6 patients) amputation. Results:The mean follow-up period was 10 years (range, 5-15 years). The overall rate of local recurrence was 14%, 22% in Group Ⅰ, and only 4% in Group Ⅱ and Group Ⅲ. According to the Musculoskeletal Tumour Society(MSTS) score for functional outcome, the mean overall score for Group I was 27.9 (out of 30), 15.9 for Group Ⅱ. Of note, the 9 patients within Group Ⅱ who received endoprosthetic reconstruction, the mean overall MSTS functional score was 25.5. Conclusion:Intralesional curettage with adjuvant therapies and filling agents is often associated with a relatively high recurrence rate, however joint function is well preserved. Patients with more extensive, biologically aggressive, and/or recurrent tumours are best treated with en-bloc resection. Objective:Giant cell tumours(GCT) represent one of the most common benign tumours of bone. However, despite its benign nature they are aggressive lesions that have a tendency to recur. This study aims to report experience with the treatment of GCTs, and reviews the relationship between surgical management and clinical outcome. Methods:A retrospective review was performed with 70 patients (32 males and 38 females) who presented to our institution between 1991 and 2001 with GCT of bone. An evaluation of the oncological and functional results was conducted and patients were divided into three groups according to the treatment method; Group Ⅰ :(46 patients) intralesional curettage and adjuvant therapy and packing with filling materials. Group Ⅱ :(18 patients) en-bloc resection and arthrodesis or reconstruction. Group Ⅲ :(6 patients) amputation. Results:The mean follow-up period was 10 years (range, 5-15 years). The overall rate of local recurrence was 14%, 22% in Group Ⅰ, and only 4% in Group Ⅱ and Group Ⅲ. According to the Musculoskeletal Tumour Society(MSTS) score for functional outcome, the mean overall score for Group I was 27.9 (out of 30), 15.9 for Group Ⅱ. Of note, the 9 patients within Group Ⅱ who received endoprosthetic reconstruction, the mean overall MSTS functional score was 25.5. Conclusion:Intralesional curettage with adjuvant therapies and filling agents is often associated with a relatively high recurrence rate, however joint function is well preserved. Patients with more extensive, biologically aggressive, and/or recurrent tumours are best treated with en-bloc resection.
出处 《Journal of Nanjing Medical University》 2008年第2期107-110,共4页 南京医科大学学报(英文版)
关键词 giant-cell tumour of bone treatment RECURRENCE OUTCOMES giant-cell tumour of bone treatment recurrence outcomes
  • 相关文献

参考文献11

  • 1K. Labs,Carsten Perka,Richard G. Schmidt.Treatment of stages 2 and 3 giant-cell tumor[J].Archives of Orthopaedic and Trauma Surgery (-).2001(1-2)
  • 2Jaffe HL,Lichtenstein L,Portis RB.Giant cell tumor of bone. its pathologic appearance, grading, supposed variants and treatment[].Archives of Pathology.1940
  • 3Sanerkin NG.Malignancy, aggressiveness, and recurrence in giant cell tumor of bone[].Cancer.1980
  • 4Prosser GH,Baloch KG,Tillman RM,Carter SR,Grimer RJ.Does Curettage without Adjuvant Therapy Provide Low Recurrence Rates in Giant-Cell Tumours of Bone[].Clinical Orthopaedics.2005
  • 5SaizP,Virkus W,Piasecki P,Templeton A,Shott S,Gitelis S.Results of giant cell tumour of bone treated with intralesional excision[].Clinical Orthopaedics.2004
  • 6Saglik Y,Yildiz Y,Karakas A,Ogüt H,Erekul S.Giant cell tumour of bone[].Bull Hosp Jt Dis.1999
  • 7Donati D,Giacomini S,Gozzi E,Salphale Y,Mercuri M,Mankin HJ, et al.Allograft Arthrodesis Treatment of Bone Tumours: A Two-Center Study[].Clinical Orthopaedics.2002
  • 8Yip KM,Leung PC,Kumita SM.Giant cell tumour of bone[].Clinical Orthopaedics.1996
  • 9Bickels J,Wittig JC,Kollender Y,Henshaw RM,Kellar-Graney KL,Meller I, et al.Distal Femur Resection With Endoprosthetic Reconstruction: a long-term followup study[].Clinical Orthopaedics.2002
  • 10Malawer MM,,Bickels J,Meller I,Buch RG,Henshaw RM,Kollender Y.Cryosurgery in the treatment of giant cell tumour. a long-term follow-up study[].Clinical Orthopaedics.1999

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部